Papers
1
Total Citations
142
H-Index
1
About
Yue Du is a pioneering researcher at the intersection of synthetic biology and gastrointestinal medicine, whose work has revolutionized the use of engineered probiotics for diagnosing and treating inflammatory bowel disease (IBD). Du’s landmark 2022 study, cited over 140 times, introduced a groundbreaking "biomarker-responsive" probiotic that not only detects IBD-associated molecular signals in mice but also records disease activity and actively ameliorates inflammation. This dual diagnostic-therapeutic platform represents a major leap forward in living therapeutics, offering a programmable, non-invasive approach to managing chronic gut disorders. By integrating biosensor circuits with therapeutic payloads, Du’s research has opened new avenues for precision medicine, enabling real-time monitoring and intervention directly at the disease site. The high citation count of this work underscores its profound impact on both the synthetic biology and gastroenterology communities, positioning Du as a leader in the emerging field of engineered living diagnostics. Their contributions hold transformative potential for translating microbial therapies from bench to bedside, promising smarter, more responsive treatments for patients with IBD and other inflammatory conditions.
Research Focus
Key Achievements
Top Papers
- 1